Stryker Corporation $SYK Stock: Vestor Capital LLC Boosts Holdings

Vestor Capital LLC grew its stake in Stryker Corporation (NYSE:SYK) by 183.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 3,238 shares of the medical technology company’s stock after purchasing an additional 2,096 shares during the quarter. Vestor Capital LLC’s holdings in Stryker were worth $892,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of SYK. International Assets Investment Management LLC increased its position in shares of Stryker by 1,432.8% during the 3rd quarter. International Assets Investment Management LLC now owns 25,000 shares of the medical technology company’s stock worth $6,885,000 after purchasing an additional 23,369 shares during the last quarter. Amundi boosted its holdings in shares of Stryker by 18.3% in the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock valued at $392,402,000 after buying an additional 192,447 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Stryker by 8.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock valued at $270,642,000 after buying an additional 65,333 shares during the last quarter. Veritas Asset Management LLP bought a new position in shares of Stryker in the second quarter valued at $168,057,000. Finally, Bank of America Corp DE bought a new position in shares of Stryker in the second quarter valued at $1,404,284,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on SYK. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Stryker in a research report on Thursday, October 29th. Barclays decreased their price objective on shares of Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research report on Friday, October 30th. BTIG Research decreased their price objective on shares of Stryker from $316.00 to $304.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Rothschild & Co Redburn lowered their price objective on shares of Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. Finally, Leerink Partners dropped their target price on shares of Stryker from $403.00 to $353.00 and set an “outperform” rating on the stock in a report on Friday, October 9th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and an average target price of $342.19.

Stryker Stock Down 0.1%

SYK opened at $325.69 on Tuesday. The stock’s fifty day simple moving average is $292.26 and its 200 day simple moving average is $323.41. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33. The stock has a market cap of $123.99 billion, a PE ratio of 34.69, a price-to-earnings-growth ratio of 2.33 and a beta of 0.78. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company had revenue of $6.52 billion for the quarter, compared to the consensus estimate of $6.62 billion. During the same period last year, the firm earned $3.19 earnings per share. The company’s revenue for the quarter was up 7.6% compared to the same quarter last year. As a group, research analysts expect that Stryker Corporation will post 14.84 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. The trade was a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 901,267 shares of company stock valued at $297,123,701. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.

The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Founded in 1941 by orthopedic surgeon Dr.